Disease-Free Survival
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
George Q Zhang, Jeffrey A Meyerhardt, Qian Shi, Tyler Twombly, Levi Pederson, Chao Ma, Juha P Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Eileen M O'Reilly, Marios Giannakis, Shuji Ogino, Adham Jurdi, Shruti Sharma, Alexey Aleshin, Anthony F Shields, Jonathan A Nowak
JAMA Oncol 12(2) 149-158
IMPORTANCE: Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer. While randomized clinical trials have not shown benefit across all patients, these findings suggest that select subgroups may benefit from their use. Despite the well-established prognostic value of circulating tumor DNA (ctDNA), its role in guiding treatment remains unclear. OBJECTIVE: To investigate the predictive value of postoperative ctDNA for survival outcomes with adjuvant celecoxib alongside conventional chemotherapy in patients with stage III colon cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer. Patients consented to biospecimen collection and had ctDNA analysis performed. Data analysis was performed from September 2024 to June 2025. EXPOSURES: Postoperative ctDNA positivity was determined using a clinically validated, tumor-informed 16-plex-polymerase chain reaction-next-generation sequencing assay (Signatera; Natera Inc) performed between surgery and initiation of adjuvant therapy. MAIN OUTCOMES AND MEASURES: Disease-free survival (DFS) and overall survival (OS). Survival by ctDNA status and adjuvant celecoxib use were assessed as part of a post hoc companion study with prespecified statistical analysis plan. RESULTS: Among 940 patients (mean [SD] age, 60.9 [10.8] years; 426 female [45.3%] and 515 male [54.7%] individuals; 222 [23.6%] with prior low-dose aspirin use; and median follow-up of 6.0 [95% CI, 6.0-6.0] years), 767 (81.6%) were ctDNA negative and 173 (18.4%) were ctDNA positive. ctDNA positivity was highly prognostic of worse DFS (reference, ctDNA negativity; adjusted hazard ratio [aHR], 6.12; 95% CI, 4.66-8.03) and OS (aHR, 5.86; 95% CI, 4.19-8.19). In patients with ctDNA positivity, celecoxib was associated with improved DFS (aHR, 0.61; 95% CI, 0.42-0.89) and OS (aHR, 0.62; 95% CI, 0.40-0.96) compared to placebo. Among patients with ctDNA negativity, celecoxib did not provide survival benefit (DFS: aHR, 0.76; 95% CI, 0.53-1.09; OS: aHR, 0.85; 95% CI, 0.54-1.36), although the interaction was not significant (P for interaction, .41 and .33 for DFS and OS, respectively). These findings persisted when stratifying patients by microsatellite instability status and PIK3CA mutational status. CONCLUSION AND RELEVANCE: The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01150045.
3 个 Figure · 8 个 KM 面板
Figure 1. Disease-Free Survival (DFS) and Overall Survival (OS) Estimates, by Postoperative Circulating Tumor DNA (ctDNA) status. [A] DFS [B] OS Disease-free survival and overall survival, stratified by postoperative ctDNA status. Data cutoff was 6 years after time of randomization.
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. Disease-Free Survival (DFS) and Overall Survival (OS) Estimates, by Assigned Oral Agent (Celecoxib vs. Placebo) and Postoperative Circulating Tumor DNA (ctDNA) Status. [A] DFS [B] OS Disease-free survival and overall survival, stratified by assigned oral agent (celecoxib or placebo) and postoperative ctDNA status in 2×2 fashion. Data cutoff was 6 years after time of randomization.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Disease-Free Survival (DFS) by Celecoxib vs. Placebo and Circulating Tumor DNA (ctDNA) Status Among Select Subgroups of Interest. [A] Non-MSI-High [B] MSI-High [C] PIK3CA Wildtype [D] PIK3CA Mutant Disease free survival, stratified by assigned oral agent (celecoxib or placebo) and postoperative ctDNA status in 2×2 fashion. Shown are subgroups of patients with A: non-microsatellite instability high tumors (non-MSI-High), B: microsatellite instability high tumors (MSI-High), C: PIK3CA wildtype tumors, and D: PIK3CA mutant tumors. Data cutoff was 6 years after time of randomization.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。